Table 2.

The factors related to the levels of ADCC fold induction and neutralization ED₅₀ among the COVID-19 patients by generalized estimation equation

Factors	ADCC fold induction		Neutralization ED50a
	β (95% CI)	P	β (95% CI)	P
Age, years
<45	1.00 (reference)		1.00 (reference)
45–60	0.042 (−0.112, 0.197)	0.591	0.060 (−0.096, 0.216)	0.452
≥60	−0.053 (−0.208, 0.101)	0.499	0.119 (−0.045, 0.282)	0.155
Sex
Male	1.00 (reference)		1.00 (reference)
Female	−0.079 (−0.218, 0.06)	0.267	−0.016 (−0.154, 0.123)	0.823
Clinical type
Asymptomatic	1.00 (reference)		1.00 (reference)
Mild	0.153 (−0.124, 0.43)	0.278	−0.244 (−0.508, 0.020)	0.070
Moderate	0.265 (0.001, 0.529)	0.049	0.094 (−0.159, 0.347)	0.468
Severe	0.549 (0.279, 0.818)	<0.001	0.225 (−0.036, 0.486)	0.091
Day from symptom onset to sampling
1−10 days	1.00 (reference)		1.00 (reference)
11–20 days	0.459 (0.299, 0.619)	<0.001	0.142 (−0.006, 0.290)	0.060
21–30 days	0.226 (0.021, 0.432)	0.031	0.393 (0.253, 0.532)	<0.001
1–6 months	−0.292 (−0.445, −0.138)	<0.001	0.234 (0.081, 0.388)	0.003
1 year	−0.047 (−0.259, 0.165)	0.665	−0.035 (−0.254, 0.185)	0.756

ADCC antibody-dependent cell-mediated cytotoxicity, CI confidence interval, COVID-19 coronavirus disease 2019

^aThe value of neutralization ED₅₀ was log₁₀-transformed